Context Therapeutics Inc.

Contributing Author

Recent Articles by Context Therapeutics Inc.

5 hours	Context Therapeutics Reports First Quarter 2026 Operating and Financial Results CNTX GlobeNewswire
Apr-02	Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer CNTX GlobeNewswire
Mar-23	Context Therapeutics Reports Full Year 2025 Operating and Financial Results CNTX +5.30% CNTX GlobeNewswire
Mar-19	Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 CNTX GlobeNewswire
Feb-09	Context Therapeutics to Participate in Upcoming Investor Conferences CNTX GlobeNewswire
Jan-16	Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNTX +6.94% CNTX -5.26% GlobeNewswire
Nov-07	Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting CNTX GlobeNewswire
Nov-05	Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results CNTX -5.31% CNTX GlobeNewswire
Oct-28	Context Therapeutics to Participate in Upcoming Investor Conferences CNTX GlobeNewswire
Oct-06	Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting CNTX +10.00% GlobeNewswire
Oct-03	Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CNTX +10.03% GlobeNewswire
Aug-27	Context Therapeutics to Participate in Upcoming Investor Conferences CNTX GlobeNewswire
Aug-06	Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results CNTX GlobeNewswire
Jun-02	Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting CNTX GlobeNewswire
May-29	Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer CNTX GlobeNewswire
May-12	Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNTX +5.14% CNTX GlobeNewswire
May-07	Context Therapeutics Reports First Quarter 2025 Operating and Financial Results CNTX GlobeNewswire
May-05	Context Therapeutics Announces Chief Medical Officer Transition CNTX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)